Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09AOO
|
|||
| Former ID |
DCL001141
|
|||
| Drug Name |
ANAVEX 2-73
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [1], [2] | |
| Cognitive impairment [ICD-11: 6D71; ICD-10: F06.7; ICD-9: 295] | Phase 1 | [3] | ||
| Infantile spasm [ICD-11: 8A62.0] | Phase 1 | [1] | ||
| Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Phase 1 | [1] | ||
| Rett syndrome [ICD-11: LD90.4; ICD-10: F84.2] | Phase 1 | [1] | ||
| Company |
Anavex
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C19H24ClNO
|
|||
| Canonical SMILES |
CN(C)CC1CCOC1(C2=CC=CC=C2)C3=CC=CC=C3.Cl
|
|||
| InChI |
1S/C19H23NO.ClH/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17;/h3-12,18H,13-15H2,1-2H3;1H
|
|||
| InChIKey |
FEQOLYDPQKHFTD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 195615-84-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Muscarinic acetylcholine receptor M1 (CHRM1) | Target Info | Agonist | [1], [2] |
| Opioid receptor sigma 1 (OPRS1) | Target Info | Agonist | [4] | |
| KEGG Pathway | Calcium signaling pathway | |||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Cholinergic synapse | ||||
| Regulation of actin cytoskeleton | ||||
| Panther Pathway | Alzheimer disease-amyloid secretase pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Muscarinic acetylcholine receptor 1 and 3 signaling pathway | ||||
| Reactome | Muscarinic acetylcholine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
| miR-targeted genes in lymphocytes - TarBase | ||||
| Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | ||||
| Regulation of Actin Cytoskeleton | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Secretion of Hydrochloric Acid in Parietal Cells | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | 2011 Pipeline of Anavex. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.